Arzneimittel

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Aug 31, 2028 · 665 days left·Open·Supplies

Registrieren zum Speichern Open documents

Structured notice only

Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

53/100

Opportunity Score

Needs reviewMedium complexity

SuppliesOpen

Warum diese Bewertung?

Chance

53 / 100

Komplexität

62 / 100

Risikofaktoren

Demand depends on insurance membership, prescribing behaviour, pharmacy dispensing and stocking behaviour, and other ma...

The authority may end the Open-House process early, particularly after exclusive rebate agreements are concluded; exist...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Eckdaten der Ausschreibung

Öffentlicher Auftraggeber: AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Land: Deutschland
CPV: 33600000 - Pharmaceutical products
Frist: Aug 31, 2028

Überblick

Moderate opportunity

Wichtige Fakten

Supplies contract
1 lot
Duration until Aug 2028
Supply of pharmaceutical products covered by non-exclusive rebate agreements for Orylmyte(R) (ATC code V01AA03), including relevant parallel and re-imported products.
The arrangement applies in Germany, with the structured place of performance identified as Dresden; the XML notice additionally describes the geographic scope as Germany and the federal states of Saxony and Thuringia.

Vollständige Zusammenfassung anzeigen

Open-House framework-style arrangement for non-exclusive pharmaceutical rebate agreements covering Orylmyte(R) (ATC V01AA03), including parallel and re-imported products, for AOK PLUS. Participation is open during the stated period to pharmaceutical companies that satisfy and accept the fixed conditions. No individual negotiations or delivery exclusivity apply, and demand and minimum quantities are not guaranteed. The participation documents and rebate terms were not provided for analysis.

Risiken

Demand depends on insurance membership, prescribing behaviour, pharmacy dispensing and stocking behaviour, and other ma...

The authority may end the Open-House process early, particularly after exclusive rebate agreements are concluded; exist...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

Participation is limited to pharmaceutical entrepreneurs within the meaning of § 4(18) AMG for the offered medicinal products.
A pharmaceutical entrepreneur must have its registered seat within the scope of the AMG, another EU Member State, or another EEA contracting state for medicinal products within...
Local representatives may participate only if they themselves qualify as pharmaceutical entrepreneurs for the relevant products.

Anforderungen können unvollständig sein.

Auftraggeber

Name

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen

Ort

Dresden, DEU

E-Mail

[email protected]

Website

www.aok.de/pk/plus/

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Orylmyte(R) Pharmaceutical Rebate Agreement

Non-exclusive rebate agreement under § 130a(8) SGB V through an Open-House model for Orylmyte(R), including parallel and re-imported products. Contracting may occur during the participation period, with no guaranteed minimum purchase quantity and possible early termination if exclusive rebate agreements are concluded.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Aug 2026 - Aug 2028

Kategorie

Pharmaceutical products

Frist

Deadline Aug 31, 2028

Vergabedetails

Veröffentlichungsdatum: 09 Jul 2026
Sprachen: German

Referenzmetadaten

Rechtsgrundlage: 32014L0024

Referenz-IDs

Ausschreibungs-ID: 477816-2026

Dokumente (1)

Vergabedokument 1